Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda
British Journal of Ophthalmology · 2024
DOI: 10.1136/bjo-2022-322683 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Ophthalmology, 2024. Verfasst von Noelle Whitestone und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Services, Orbis International, New York, New York, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Artificial Intelligence, Feasibility Studies, Mass Screening. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Association for Research in Vision and Ophthalmology Roche Award, Orbis International.
Abstract (Originalsprache)
Background
Evidence on the practical application of artificial intelligence (AI)-based diabetic retinopathy (DR) screening is needed.
Methods
Consented participants were screened for DR using retinal imaging with AI interpretation from March 2021 to June 2021 at four diabetes clinics in Rwanda. Additionally, images were graded by a UK National Health System-certified retinal image grader. DR grades based on the International Classification of Diabetic Retinopathy with a grade of 2.0 or higher were considered referable. The AI system was designed to detect optic nerve and macular anomalies outside of DR. A vertical cup to disc ratio of 0.7 and higher and/or macular anomalies recognised at a cut-off of 60% and higher were also considered referable by AI.
Results
Among 827 participants (59.6% women (n=493)) screened by AI, 33.2% (n=275) were referred for follow-up. Satisfaction with AI screening was high (99.5%, n=823), and 63.7% of participants (n=527) preferred AI over human grading. Compared with human grading, the sensitivity of the AI for referable DR was 92% (95% CI 0.863%, 0.968%), with a specificity of 85% (95% CI 0.751%, 0.882%). Of the participants referred by AI: 88 (32.0%) were for DR only, 109 (39.6%) for DR and an anomaly, 65 (23.6%) for an anomaly only and 13 (4.73%) for other reasons. Adherence to referrals was highest for those referred for DR at 53.4%.
Conclusion
DR screening using AI led to accurate referrals from diabetes clinics in Rwanda and high rates of participant satisfaction, suggesting AI screening for DR is practical and acceptable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Services, Orbis International, New York, New York, USA.
- RIIO iHospital, Rwanda International Institute of Ophthalmology, Kigali, Rwanda.
- Department of Ophthalmology, Rwanda Military Hospital, Kigali, Rwanda.
- Department of Ophthalmology, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.
- Centre for Public Health, Queen's University Belfast, Belfast, UK.
- Clinical Services, Orbis International, New York, New York, USA ciku.mathenge@riio.org.
ORCID-Profile: Noelle Whitestone, Nathan Congdon
Förderung
- Association for Research in Vision and Ophthalmology Roche Award
- Orbis International
Zitieren
APA
Whitestone, N., Nkurikiye, J., Patnaik, J. L., Jaccard, N., Lanouette, G., Cherwek, D. H., Congdon, N., & Mathenge, W. (2024). Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2022-322683
Vancouver
Whitestone N, Nkurikiye J, Patnaik JL, Jaccard N, Lanouette G, Cherwek DH, et al. Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda. British Journal of Ophthalmology. 2024. doi:10.1136/bjo-2022-322683
BibTeX
@article{Whitestone2024,
author = {Whitestone, Noelle and Nkurikiye, John and Patnaik, Jennifer L and Jaccard, Nicolas and Lanouette, Gabriella and Cherwek, David H and Congdon, Nathan and Mathenge, Wanjiku},
title = {Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda},
journal = {British Journal of Ophthalmology},
year = {2024},
doi = {10.1136/bjo-2022-322683}
}
EUVIMED